第 = $( +) 行情回顾 01 02 板块观点和投资组合 03 行业和个股事件 本周行情回顾 本周中信一级行业指数涨跌幅 本周涨幅排名前/后十名的股票 倍益康 廣農制药 -24.51% 8.12% 无锡品海 *ST景ច -24.419 20.70% 1% 荣昌生物 中科学费 16.72% 0% 受用医疗 15.90% 三次降行 -1% 咖降药业 维康药业 15.10% -2% 科兴制药 海月药业 14.21% -3% 恩威医药 13.799 博迅生物 -4% 华森制药 11.55% 鹿得医疗 -5% 普瑞眼科 润都股份 11.26% -6 欧康医药 兴并眼药 10.46% -14.24% 15% 20% 25% 30% 35% -30% -25% -20% -15% -10% -5% 0% રેક્ટ 10% 证监会审核华创证券投资咨询业务资格批文号：证监许可（2009）1210 号 未经许可，禁止转载 资料来源: Wind, 华创证券 1 华创研究 ω · 本周，中信医药指数上涨1.08%，跑输沪深300指数0.03个百分点，在中信30个一级行业中排名第18位。 · 本周涨幅前十名股票为康惠制药、*ST ...

证券研究报告 医药生物行业生命科学服务系列报告（一） ——海外公司 Bio-Techne & Thermo Fisher 西部证券研发中心 2025年3月14日 分析师 | 李梦园 S0800523010001 邮箱地址 limengyuan@research.xbmail.com.cn 分析师 | 谭雨露 S0800524100004 邮箱地址 tanyulu@research.xbmail.com.cn 核心结论 CONTENTS 目 录 CONTENTS 目 录 02 Thermo Fisher 公司概述 01 Bio-Techne 公司概述 生命科学服务国内相关标的 03 Bio-Techne 公司介绍 3.1 3.6 4.5 5.0 5.6 6.4 7.1 7.4 9.3 11.1 11.4 11.6 5.9 15.2% 26.4% 10.3% 12.8% 14.2% 11.0% 3.5% 26.0% 18.7% 2.8% 2.0% 6.7% 0% 5% 10% 15% 20% 25% 30% 0 2 4 6 8 10 12 14 2013 2015 2017 2019 2021 2023 2025 ...

南方财经全媒体集团全国两会报道组 作 者丨周潇枭 编 辑丨张星 3月5日，十四届全国人大三次会议开幕会举行，国务院总理李强作政府工作报告。 政府工作报告指出，2 0 2 5年经济增长预期目标为5%左右，既是稳就业、防风险、惠民生的需 要，也有经济增长潜力和有利条件支撑，并与中长期发展目标相衔接，突出迎难而上、奋发有 为的鲜明导向。 政府工作报告指出，要实施更加积极的财政政策，实施适度宽松的货币政策。政府工作报告还 对今年的重点工作进行部署，包括大力提振消费、提高投资效益，因地制宜发展新质生产力， 深入实施科教兴国战略，推动标志性改革举措加快落地，扩大高水平对外开放，有效防范化解 重点领域风险等。 完成5%左右的增长目标有哪些支撑条件？如何看待更加积极的财政政策和适度宽松的货币政 策组合？如何大力提振消费？如何提高投资效益？有哪些重点产业赛道值得关注？当前应推动 哪些重点改革事项落地？带着这些问题2 1世纪经济报道记者专访了中国宏观经济研究院院长 黄汉权。 黄汉权。资料图 以新质生产力为驱动的发展态势在逐步形成 《2 1世纪》 ：2 0 2 4年我国G D P规模接近1 3 5万亿元，同比增长5 %。如何看待中 ...

报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 百赛生物为科研客户提供分子生物学、细胞生物学、免疫学、生物化学、生态学、食品药品检验及临床检测等 领域的耗材、试剂、仪器及相关配套服务。公司旗下拥有多个自主品牌，包括"百赛利德BioLeader"（常规耗 材）、"海利克思Double-Helix"（通用试剂）和"百赛义器BioInstru"（小型仪器），同时代理康宁、爱思 进、颇尔、麦迪康等国际一流品牌。 合作伙伴征集：2025全球手术机器人大会 融资历程 • 2020年，完成首轮战略融资。 报名：首届全球骨科大会 | 奖项评选 2025年3月4日， 百赛生物 宣布完成新一轮 近亿元 融资，由华盖资本独家投资。 本轮资金将用于并购整 合、自主开发加速自主品牌产品线建设、构建现代化供应链体系、加强数字化电商平台建设等，以提升服务全 球客户的能力。 # 关于百赛生物 百赛生物成立于2005年，是中国专注于生命科学实验室快速消耗品的公司。总部位于上海，拥有26个办事处 和分公司，员工总数超过600人，年收入超10亿元。 业务范围 • 医疗健康：康泰生物、海吉亚医疗、华大智造。 • 科技： ...

SLR Investment (SLRC) Q4 2024 Earnings Call February 26, 2025 10:00 AM ET Company Participants Michael Gross - Chairman, President & Co-CEOShiraz Kajee - CFO, Treasurer & SecretaryBruce Spohler - Co-CEO, COO & Interested DirectorErik Zwick - Managing Director, Equity ResearchMelissa Wedel - Vice President, Equity ResearchPaul Johnson - Vice President Conference Call Participants Casey Alexander - Senior Vice President & Research Analyst Operator Good day, everyone, and welcome to the Q4 twenty twenty four S ...

已为全球超过300家客户提供服务，业务覆盖20多个国家和地区。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，杭州领挚科技有限公司（LinkZill，以下简称"领挚科技"）日前完成由比邻星创 投独家投资的数千万元A轮融资。本轮融资将用于加速产品交付及全球市场拓展。 领挚科技于2019年成立，总部位于中国杭州，在英国剑桥设有研发及商务中心。 2023年，领挚科 技投资建设了杭州薄膜晶体管（Thin-Film Transistor，以下简称TFT）半导体研发中心，用于聚 焦TFT半导体技术在生命科学、新型传感及显示等领域的全球交叉产业化发展。目前，领挚科技已为 全球超过300家客户提供服务，业务覆盖20多个国家和地区 。 领挚科技杭州总部 领挚科技团队核心成员毕业于国内外顶尖高校，曾任职于行业头部企业，精通TFT芯片设计到系统集 成全流程技术，专业素养卓越。此外，公司还集合了生命科学产业、客户、供应商等多方精英，组成 了多元高效的优质团队。我们坚信，随着生命科学与半导体技术的深度融合，领挚科技的产品和服务 将为全球生命科学领域带来革命性的变化。我们期待 ...

Financial Data and Key Metrics Changes - The company generated total adjusted revenues of $730 million in Q4 2024, resulting in 6% organic growth, which was above expectations [18] - For the full year, total adjusted revenue was $2.76 billion, with 1% organic growth [19] - Adjusted EPS for Q4 was $1.42, exceeding guidance by $0.04, and for the full year, adjusted EPS was $4.90, representing 5% growth year over year [21][22] Business Line Data and Key Metrics Changes - Life Sciences segment generated $336 million in Q4, up 5% on both a reported and organic basis, but down low single digits for the full year [25] - Diagnostics segment generated $393 million in Q4, up 4% on a reported basis and 6% on an organic basis, with 4% organic growth for the full year [27] - The Life Sciences instruments revenue was down high single digits in Q4 and down low double digits for the full year [25] Market Data and Key Metrics Changes - In Q4, organic revenue growth was 5% in Life Sciences and 6% in Diagnostics, with mid single digits growth in the Americas, low single digits in Europe, and mid single digits in Asia, particularly high single digits in China [23] - For the full year, China experienced low single digit growth in diagnostics and mid teens growth in life sciences, but overall, China declined in the low single digits organically [24] Company Strategy and Development Direction - The company plans to step up strategic internal investments in 2025, expecting organic growth to improve [9][31] - A new Life Sciences Solutions business unit will be established, representing approximately 85% of the Life Sciences segment, reflecting a re-segmentation of the Applied Genomics business [14] - The company aims for adjusted operating margin expansion of 20 to 40 basis points in 2025, despite increased investments [31] Management's Comments on Operating Environment and Future Outlook - Management noted that while demand trends have stabilized, the pace of recovery remains uncertain, leading to a cautious outlook for 2025 [39] - The company expects total organic growth in 2025 to be in the range of 3% to 5%, with balanced growth expected throughout the year [30] - Management expressed optimism about the potential for recovery in the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Other Important Information - The company repurchased $185 million worth of shares in Q4, bringing total buyback activity for 2024 to $370 million [22] - Free cash flow for Q4 was $151 million, with a full year total of $578 million, equating to 96% conversion of adjusted net income [22] Q&A Session Summary Question: Insights on key end markets and recovery areas - Management acknowledged a path to recovery but emphasized uncertainty in the pace of return to normalcy, with diagnostics and software businesses showing signs of improvement while instrumentation remains a concern [39][40] Question: Guidance for China and stimulus impact - Management expects China to align with company growth averages, with modest stimulus impact anticipated [41][42] Question: Segment outlooks relative to overall guidance - Diagnostics is expected to perform above the company average, while Life Sciences is projected to be in the low single digits [46][47] Question: Expectations for reagents growth - Management indicated that the reagents business is gaining market share and is expected to grow in mid single digits for fiscal 2025 [48][50] Question: Q1 guidance and margin visibility - Management noted that Q1 margins are typically below the full year average, with a similar cadence expected as in 2024 [54] Question: Applied Genomics recovery expectations - Management expressed optimism about the recovery of the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Question: FX impact on margins - Management clarified that FX does not have a material impact on operating margins [66] Question: Strategic investments for 2025 - Management highlighted increased investments in digital capabilities and expanding sales channels as part of their strategy for 2025 [70]